BioLineRx (BLRX) Non-Current Assets (2021 - 2025)

BioLineRx has reported Non-Current Assets over the past 5 years, most recently at $17.2 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $17.2 million for Q4 2025, up 45.94% from a year ago — trailing twelve months through Dec 2025 was $17.2 million (up 45.94% YoY), and the annual figure for FY2025 was $17.2 million, up 45.94%.
  • Non-Current Assets for Q4 2025 was $17.2 million at BioLineRx, up from $11.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for BLRX hit a ceiling of $24.4 million in Q4 2022 and a floor of $11.8 million in Q4 2024.
  • Median Non-Current Assets over the past 5 years was $17.2 million (2025), compared with a mean of $18.8 million.
  • Biggest five-year swings in Non-Current Assets: plummeted 31.34% in 2023 and later surged 45.94% in 2025.
  • BioLineRx's Non-Current Assets stood at $24.0 million in 2021, then rose by 1.65% to $24.4 million in 2022, then plummeted by 31.34% to $16.7 million in 2023, then fell by 29.51% to $11.8 million in 2024, then surged by 45.94% to $17.2 million in 2025.
  • The last three reported values for Non-Current Assets were $17.2 million (Q4 2025), $11.8 million (Q4 2024), and $16.7 million (Q4 2023) per Business Quant data.